MedPath

Role of acetazolamide and hydrochlorothiazide followed by furosemide in treating edema

Phase 3
Conditions
Refractory edema in nephrotic syndrome.
Incl.: congenital nephrotic syndrome, lipoid nephrosis
Registration Number
IRCT2014081518798N1
Lead Sponsor
Shiraz Nephrourology Research Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Inclusion Criteria:
1. Having refractory edema due to nephrotic syndrome
2. Normal BUN and creatinine
3. Being able to come for weekly visit
4. More than 18 years of age
5. Signing the informed consent form

Exclusion Criteria

1. Hypokalemia
2. Pregnancy
3. Renal transplant
4. Present malignancy
5. Severe acidosis
6. Using NSAIDs
7. Having another causes of edema including liver cirrhosis, heart failure

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Weight. Timepoint: 3 weeks after the starting the drugs. Method of measurement: Using a scale.
Secondary Outcome Measures
NameTimeMethod
Blood Urea Nitrogen. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Creatinine. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Sodium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Potassium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Triglycerides. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Cholesterol. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.
© Copyright 2025. All Rights Reserved by MedPath